Following the latest clinical guidance supports evidence-based assessment, informs decision-making, and can reduce complications in patients with lymphoma. Ongoing review of recommendations and guidance enables clinicians to improve evaluation and management, which supports better patient outcomes.
Today's rundown features clinical guidelines published within the past five years from international organizations like the British Society for Hematology (BSH), European Hematology Association (EHA), and the Society for Immunotherapy of Cancer (SITC).
Recent Lymphoma Guidelines
- Clinical Management of Bispecific Antibody Therapy for Lymphoma
- British Society for Haematology (BSH), September 2025
- Large B-Cell Lymphoma (LBCL): Diagnosis, Treatment, and Follow-Up
- European Hematology Association (EHA), September 2025
- Diagnosis, Treatment and Follow-Up of Lymphomas
- European Society for Medical Oncology (ESMO), August 2025
- Peripheral T and Natural Killer-Cell Lymphomas
- European Hematology Association (EHA) / European Society for Medical Oncology (ESMO), May 2025
- Management of Relapsed or Refractory Large B-Cell Lymphoma
- British Society for Haematology (BSH), May 2025
- Immunotherapy for the Treatment of Lymphoma
- Society for Immunotherapy of Cancer (SITC), February 2025
- Human Immunodeficiency Virus-Associated Lymphomas
- European Hematology Association (EHA) / European Society for Medical Oncology (ESMO), September 2024
- Primary Central Nervous System Lymphomas
- European Hematology Association (EHA) / European Society for Medical Oncology (ESMO), June 2024
- Management of Newly Diagnosed Large B-Cell Lymphoma
- British Society for Haematology, January 2024
- Diagnosis and Management of Marginal Zone Lymphomas
- British Society for Haematology (BSH), November 2023
- Diagnosis and Management of Mantle Cell Lymphoma
- British Society for Haematology (BSH), October 2023
- Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
- Lymphoma Canada (LCA), October 2023
- Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Lymphoma Canada (LCA), September 2021
- Frontline Treatment of Diffuse Large B-Cell Lymphoma
- Lymphoma Canada (LCA), September 2021
Check out other clinical guidelines and sign up for alerts to stay informed on the latest published guidelines and insights.
Copyright © 2026 Guideline Central, all rights reserved.